Evidence map›Paper›PMID 41324724›Full record

ReviewCurrent hypertension reports2025

Blood Pressure-Lowering Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists.

Ahmed Kamal Siddiqi, Muhammad Shahzeb Khan, Anandita Kulkarni, Michael E Hall, Michael Böhm, Javier Díez, Javed Butler

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current hypertension reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ahmed Kamal SiddiqiDivision of Cardiothoracic Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA.
Muhammad Shahzeb KhanDepartment of Medicine, Baylor College of Medicine, Temple, TX, USA.
Anandita KulkarniBaylor Scott and White Health: The Heart Hospital Plano, Plano, TX, USA.
Michael E HallDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Michael BöhmDepartment of Internal Medicine III, Saarland University Hospital, Saarland University, Homburg, Germany.
Javier DíezCenter for Applied Medical Research (CIMA), School of Medicine, University of Navarra, Pamplona, Spain.
Javed ButlerBaylor Scott and White Research Institute Dallas, Dallas, TX, USA. Javed.butler@bswhealth.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewHypertension is the leading modifiable risk factor for cardiovascular disease. Despite multiple antihypertensive therapies, blood pressure (BP) control remains suboptimal in many individuals with persistent cardiovascular risk. This review evaluates the antihypertensive potential of sodium-glucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP-1RA), particularly in patients with comorbid diabetes, HF, CKD or resistant hypertension. RECENT

findingsSGLT2-i consistently lower office SBP/DBP (2.5-4.0/1.5-2.0 mmHg) and 24-hour ambulatory BP (3.8/1.8 mmHg). GLP-1RAs show modest SBP reductions (1.8-5.1 mmHg) and minimal DBP effects (~ 0.5 mmHg), though tirzepatide shows greater efficacy (~ 10.6 mmHg) in select populations. Both classes have demonstrated cardio-renal benefits, favorable safety profiles, and reduced polypharmacy. SGLT2-i exert more consistent BP-lowering effects than GLP-1RA, largely due to their diuretic-like action. While not first-line therapies, both drug classes show promise as adjuncts in high-risk populations. Future research should further define their role in comprehensive hypertension management.

Indexed as

Antihypertensive AgentsBlood PressureGlucagon-Like Peptide-1 Receptor AgonistsHypertensionSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2HumansAntihypertensive AgentsGlucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 InhibitorsComorbiditiesDiabetes mellitusGLP-1RAGlucagon-like peptide-1 receptor agonistsHeart failureHypertensionObesityResistant hypertensionSGLT2-ISodium-glucose co-transporter 2 inhibitors

Identifiers

PMID41324724

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.